Ucb Biopharma SPRL
119 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
Recorded as renamed to Ucb Biopharma SRL (2020)
28
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 2 to 4, 2026 · next Dec 2
- 3 fees due Jan 9 to 23, 2027 · next Jan 9
- 2 fees due Feb 6 to 13, 2027 · next Feb 6
- 2 fees due May 5 to 19, 2027 · next May 5
- 1 fee due Jun 3, 2027The maintenance fee for A Specific Trifluoroethyl Quinoline Analogue For Use In The Treatment Of Sjögren's SyndromS (US 10,493,074) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Fused Pentacyclic Imidazole Derivatives (US 11,912,721) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 2 fees due Sep 15 to 17, 2027 · next Sep 15
- 3 fees due Oct 14 to 21, 2027 · next Oct 14
- 4 fees due Nov 5 to 10, 2027 · next Nov 5
Recent changes
- 6 terms have ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D676,552 | Needle cap for a medication administration device In force · From the USPTO record | In force | From the USPTO record | |
| US 7,888,344 | Fused thiazole derivatives as kinase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 7,910,618 | Albumin-Binding Conjugates Comprising a Fatty Acid and Peg In force · High confidence | In force | High confidence | |
| US 7,989,594 | Modified Antibody Fab Fragments In force · High confidence | In force | High confidence | |
| US 8,633,194 | Pharmaceutical composition of piperazine derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 8,617,847 | Nucleic acids encoding antibody molecules which bind IL-17A and IL-17F In force · From the USPTO record | In force | From the USPTO record | |
| US 9,890,219 | Methods of treating an IL-17A mediated pathological condition In force · From the USPTO record | In force | From the USPTO record | |
| US 10,308,723 | Method of treating inflammation by administering antibody molecules which bind IL-17A and IL-17F In force · From the USPTO record | In force | From the USPTO record | |
| US 8,303,953 | Antibody molecules which bind IL-17A and IL-17F In force · From the USPTO record | In force | From the USPTO record | |
| US 8,378,073 | Process for attaching effector molecules to proteins In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 80: 119 patents in force now held by others · 127 lapsed for an unpaid fee · 24 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 10 abandoned · 35 no status recorded